pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery  by Liu, Yanhua et al.
ww.sciencedirect.com
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 5 9e1 6 7Available online at wScienceDirect
journal homepage: http : / /ees.e lsevier .com/ajps/defaul t .aspReview
pH-sensitive polymeric micelles triggered drug release for
extracellular and intracellular drug targeting deliveryYanhua Liu a, Wenping Wang a, Jianhong Yang a, Chengming Zhou a, Jin Sun b,*
aDepartment of Pharmaceutics, School of Pharmacy, Ningxia Medical University, No. 1160, Shengli Road, Yinchuan 750004, China
bDepartment of Biopharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Mailbox 59#, No. 103, Wenhua Road,
Shenyang 110016, Chinaa r t i c l e i n f o
Article history:
Received 6 May 2013
Received in revised form
6 June 2013
Accepted 15 June 2013
Keywords:
pH-sensitive polymeric micelles
Tumor extracellular pH targeting
Tumor intracellular pH targeting
Multifunctional polymeric micelles
MDR reversion* Corresponding author. Tel./fax: þ86 24 23986
E-mail address: sunjin66@21cn.com (J. Sun).
Peer review under responsibility of Shenyan
Production and hosting by El
1818-0876/$ e see front matter ª 2013 Sheny
http://dx.doi.org/10.1016/j.ajps.2013.07.021a b s t r a c t
Most of the conventional chemotherapeutic agents used for cancer chemotherapy suffer
from multidrug resistance of tumor cells and poor antitumor efficacy. Based on physio-
logical differences between the normal tissue and the tumor tissue, one effective approach
to improve the efficacy of cancer chemotherapy is to develop pH-sensitive polymeric
micellar delivery systems. The copolymers with reversible protonationedeprotonation
core units or acid-liable bonds between the therapeutic agents and the micelle-forming
copolymers can be used to form pH-sensitive polymeric micelles for extracellular and
intracellular drug smart release. These systems can be triggered to release drug in response
to the slightly acidic extracellular fluids of tumor tissue after accumulation in tumor tis-
sues via the enhanced permeability and retention effect, or they can be triggered to release
drug in endosomes or lysosomes by pH-controlled micelle hydrolysis or dissociation after
uptake by cells via the endocytic pathway. The pH-sensitive micelles have been proved the
specific tumor cell targeting, enhanced cellular internalization, rapid drug release, and
multidrug resistance reversal. The multifunctional polymeric micelles combining extra-
cellular pH-sensitivity with receptor-mediated active targeting strategies are of great in-
terest for enhanced tumor targeting. The micelles with receptor-mediated and intracellular
pH targeting functions are internalized via receptor-mediated endocytosis followed by
endosomal-pH triggered drug release inside the cells, which reverses multidrug resistance.
The pH sensitivity strategy of the polymeric micelles facilitates the specific drug delivery
with reduced systemic side effects and improved chemotherapeutical efficacy, and is a
novel promising platform for tumor-targeting drug delivery.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.320.
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a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 5 9e1 6 71601. Introduction conventional drug delivery systems, the stimulus-sensitiveCancer is a leading cause of death around the world. Themost
common cancer treatments are chemotherapy, radiation and
surgery, with chemotherapy being the major treatment mo-
dality. However, the conventional chemotherapeutic agents
are limited by their undesirable properties, such as poor sol-
ubility, low tumor targeting, insufficient cellular drug uptake,
low therapeutic efficacy, and cytotoxicity to normal tissues,
which may be the cause of treatment failure in cancer.
Currently, nanotechnology has been extensively studied for
their potential applications in cancer diagnosis and treatment
for effective cancer therapy over the years. Nano drug delivery
systems are being trialed for specific targeting-delivery of
drugs to cancer sites in order to improve the therapeutic ef-
ficacy due to improved distribution specificity, increased
internalization and intracellular drug delivery while mini-
mizing undesirable side effects [1e3].
Among the various nanotechnology approaches, the poly-
meric micelles have received considerable scientific attention
as a versatile nanomedicine platform with improved phar-
maceutical and efficacious response in the field of drug de-
livery. Polymeric micelles have been utilized as a novel
promising colloidal carriers for the targeted delivery and
controlled release of drugs, proteins and genes in the cancer
diagnosis and therapy. It is attributable to such appealing
properties as small particle size and narrow size distribution,
distinctive core-shell structure, high solubilization capacity
and structural stability, and tumor passive localization by
enhanced permeability and retention (EPR) effect for passive
targeting. Moreover, polymeric micelles can also be modified
with ligands or antibodies for active targeting to increase the
selectivity for tumor cells and enhance intracellular drug de-
livery. PEGylation of polymeric micelles can avoid recognition
and uptake by reticuloendothelial system, decrease plasma
opsonin adhesion and increase the circulation time of mi-
celles in the blood. All the above properties of polymeric mi-
celles lead to overcome the problems associated with the
conventional chemotherapy, such as nonspecific toxicity, lack
of tumor selectivity, and the development of multidrug
resistance (MDR) in various tumor cells. Therefore, the poly-
meric micellar systems have been considered as promising
anticancer drug carriers in nanotechnology [4e8].
Nowadays, although polymeric micelles have been re-
ported to accumulate preferably in tumor due to passive tar-
geting and/or receptor-mediated active targeting, the
inefficient drug release in the tumor cells can be another
barrier that may significantly lower drug’s efficacy. In order to
overcome this barrier, the polymeric micellar systems with
controlled micellar dissociation and triggered drug release
mechanism are developed. The use of stimuli-responsive
polymeric micelles offers an interesting opportunity for drug
delivery as programmable systems in the optimization of
cancer therapy. The stimuli systems enable the polymeric
micelles to release drug in response to specific external or
internal stimuli, such as temperature, pH, ultrasound or en-
zymes, by including thermo- or pH-sensitive components or
by attaching specific targeting moieties to the outer hydro-
philic surface of polymeric micelles [9,10]. Compared to thenanopreparations show a superior ability for control and
adjustment of the location and time of drug release and
internalization in the tumor cells and theirmicroenvironment
by responding to local stimuli. Among these stimuli, change in
acidity as an internal signal is particularly crucial for the
development of micellar drug carriers that facilitate tumor
targeting. The external conditions as well as internal pH
stimuli can be used to modify the behavior of the polymeric
micelles that control drug release, improve drug internaliza-
tion, control the intracellular drug fate and even allow for
certain physical interactions, resulting in an enhanced tumor
targeting and antitumor effect [11].
Table 1 summarizes some investigations of polymeric mi-
celles used to deliver various drugs via pH-sensitive targeting
in the recent years. The purpose of this review is to provide a
detailed description of the application of pH-sensitive poly-
meric micelles for tumor chemotherapy. The emphasis is
placed on more recent developments in the area of pH-
sensitive nanotechnology, particularly for those responding
to tumor extracellular pH and intracellular pH for drug tar-
geted delivery and the MDR treatment, including the multi-
functional polymeric micelles designed for tumor targeting
and MDR reversing.2. pH-sensitive polymeric micellar delivery
system
2.1. Tumor pH microenvironment
For polymeric micellar drug delivery systems, drug release
from polymeric micelles is governed by the rate of drug
diffusion, partition coefficient, micelle stability and rate of
biodegradation of the copolymers. Triggered release of a drug
from the long circulating micelle vehicles at tumor sites while
maintaining a minimal release rate during circulation, is a
very desirable property for tumor chemotherapy [25].
In cancer therapy, the tumor microenvironment is one of
the many areas which are studied to design new therapy
modality. In the stimuli-responsive delivery systems, the
anticancer agent can be released by an appropriate stimulus
of tumor area, such as pH, glucose and temperature. Among
all applied stimuli, acidic pH as an internal stimulus has been
considered as an ideal trigger for the selective release of
anticancer drugs due to the fact that the pH at both primary
and metastasized tumors is lower than the pH of normal tis-
sue. In addition, the pH targeting approach is regarded as a
more general strategy than the conventional specific tumor
cell surface targeting approaches, because the acidic tumor
microenvironment is common in solid tumors [26e28].
The existing pH of tumor tissue has been considered as an
ideal trigger for the selective release of anticancer drugs in
tumor tissues and/or within tumor cells. Compared to the
extracellular pH of normal tissues and blood constant at pH
7.4, the measured tumor extracellular pH (pHe) values of most
solid tumors range from pH 6.5 to 7.2, which is lower than the
normal tissues. Moreover, changes in pH are also encountered
once the micelles enter cells via endocytosis where pH can
Table 1 e Applications of pH-sensitive polymeric micelles for extracellular and intracellular drug targeted delivery.
Polymeric micelles Drug incorporated Properties References
N-Boc-histidine-poly[(D,L-lactide)]-co-glycolide]-
poly(ethylene glycol)-poly[(D,L-lactide)]-co-
glycolide] micelles
Doxorubicin The polymeric micelles can trigger drug release under tumor
extracellular microenvironments and exhibit excellent cellular uptake.
[12]
Poly(ethylene glycol)-cis-aconityl-chitosan-stearic
acid polymeric micelles
Doxorubicin PEGylation significantly reduced cytotoxicity of the conjugate, and
acid-triggered PEG degradation combined with DOX release was
feasible in efficient internalization to tumor cells.
[13]
Poly(histidine)-poly(ethylene glycol) and poly(D-
lactic acid)-poly(ethylene glycol)-folate mixed
micelles
Doxorubicin The cytotoxicity of micelles was approximately 7.5-fold higher than
free doxorubicin.
[14]
Galactosylated chitosan-graft-poly (N-
isopropylacrylamide) micelles
Oridonin The micelles could enhance uptake through galactose receptor-
mediated endocytosis, and the cytotoxicity enhanced due to the tumor
extracellular pH triggered drug release.
[15]
Poly(ethylene glycol)-poly(aspartate-hydrazone-
adriamycin) [PEG-p(Asp-Hyd-Adr)] micelles
Adriamycin The micelles performed an intracellular pH-triggered drug release
capability, tumor-infiltrating permeability, and effective antitumor
activity with extremely low toxicity.
[16]
AP peptide-poly(ethylene glycol)-poly(D,L-lactic acid)
(AP-PEG-PLA) and poly(ethylene glycol)-poly(b-
amino ester) (PEG-PAE) micelles
Doxorubicin Themicelles exhibited excellent cellular accumulation with AP peptide
targeting ability and triggered drug release under tumor pHe.
[17]
Poly[(D,L-lactide)]-co-glycolide]-poly(ethylene glycol)-
folate (PLGA-PEG-FOL) and poly (b-amino ester)-
poly(ethylene glycol)-folate (PAE-PEG-FOL) mixed
micelles
Doxorubicin The drug release can be triggered at endosomal pH, resulting in an
enhanced nucleus drug concentration and improved the cytotoxicity.
[18]
Monoclonal antibody 2C5-DSPE-poly(ethylene glycol)
and poly (histidine)-poly(ethylene glycol) mixed
micelles
Paclitaxel The micelles could enhance the tumor cell-specific internalization by
2C5-mediated endocytosis and trigger drug release, resulting in the
improved anticancer efficacy.
[19]
Poly(ethylene glycol)-poly(mono-2,4,6-trimethoxy
benzylidene-pentaerythritol carbonate) [PEG-b-
P(TMBPEC-co-AC)] micelles
Paclitaxel The micelles showed high anti-tumor activity with superior
extracellular stability and rapid intracellular drug release
[20]
Poly(HEMA-co-histidine)-poly(D, L-lactic acid) and
folate-poly(ethylene glycol)-poly(D, L-lactic acid)
mixed micelles
Doxorubicin The micelles exhibited great anti-tumor efficacy with folate mediated
cancer targeting and pH triggered intracellular drug delivery
[21]
Poly(ethylene glycol)-poly(L-histidine)/poly(ethylene
glycol)-poly(L-lactic acid) [PEG-PHis/PEG-PLA]
mixed micelles
Doxorubicin The micelles exhibited MDR reversing via receptor-mediated
endocytosis followed by drug release inside the cells.
[22,23]
Poly(ethylene glycol)-poly(D,L-lactic acid)-poly (b-
amino ester) [PEG-(PLA-PAE)] micelles
Doxorubicin The release of doxorubicin from the micelles was accelerated by
decreasing pH from 7.4 to 5.0.
[24]
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Fig. 2 e (a) Acid-sensitive amphiphilic block copolymers in
which the anticancer drugs are conjugated to the side
chain of the core-forming segments through the acid-liable
bonds; (b) pH-sensitive polymeric micelles are stable under
physiological condition (pH 7.4) but gradually release drugs
under acidic environment such as solid tumors,
endosomes and lysosomes through the cleavage of the
acid-labile bonds; (c) chemical structures of acid liable
chemical bonds [29].
Fig. 1 e Schematic illustrationof variouspHgradientsofnormal tissue, bloodand tumor tissue aswell as endosomeelysosome
process [26].
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(Fig. 1). The pH gradient is caused by hypoxia that upregulates
glycolysis, followed by the production of lactate and protons
in extracellular microenvironments. The low pH in tumor
extracellular space or in various subcellular organelles is a
significant signal for targeting. Therefore, the acidity in the
tumor microenvironment and endosomes has been the most
utilized stimulus for the design of the stimulus-sensitive
nanopreparations. Differences in pH between the normal tis-
sues and the tumor tissues, as well as the acidic environment
in endosomal and lysosomal compartments, can be exploited
as an internal stimulus for triggered drug release, and pH-
sensitive drug release is competitive and favorable for
chemotherapy [29,30].
Therefore, the pH-sensitive polymeric micelles for target-
ing drug delivery to tumors are stable at physiological pH but
deformed to facilitate release of the drug under mild acidic
conditions outside or inside tumor cells, which may result in
significantly enhanced therapeutic efficacy and minimal side
effects. Polymeric micelles may be designed to display
tunable pH sensitivity and controlled release by introduction
of ionizable amino groups into their backbones. The
pH-sensitive polymeric micelles can be designed to carry,
deliver, and control the release of hydrophobic agents in
tumor tissue by relying on the EPR effects and the low pH in
the vicinity of tumor tissue. Drug release from micelles at the
targeted tumor area can be enhanced by applying an internal
or external trigger. These systems increase drug accumulation
at tumor sites or at intracellular compartments in tumor cells
with less drug distribution and thereby decreased damage to
the normal tissues [31].
2.2. The pH-sensitive strategies
The pH-sensitive nanocarriers can be constructed from
stimuli-responsive polymers that are able to sense small
changes in microenvironmental pH and the pH triggers a
corresponding change in the polymer’s physical properties
such as size, shape or hydrophobicity. The pH-sensitivepolymeric micellar systems developed by two main strate-
gies are used to fabricate pH-sensitive drug delivery systems.
One approach is utilization of pH-labile chemical bonds (pH-
sensitive polymer-drug conjugates), such as hydrazone, cis-
acotinyl and acetal bonds. Presence of acid-labile linkages
between drug and polymer enables drug release either in
relatively acidic extracellular fluids in a tumor, or after
endocytosis in endosomes or lysosomes in tumor cells. In
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inserted into the main chain, side chain or at the terminal of
the core-forming blocks (Fig. 2). In general, these bonds are
stable at neutral or alkaline pH but occur hydrolytic cleavage
at acid pH. In other words, the micelles are relatively stable at
blood pH 7.4, but start to release the drugs under acidic con-
ditions [32e34].
The hydrazone linkers have been used extensively in
polymeric conjugates of anticancer drugs for acid-triggered
drug release. Bae et al. prepared micelles based on mPEG-b-
poly(aspartate hydrazone doxorubicin) where doxorubicin
(DOX) was conjugated to the hydrophobic segments through
acid-sensitive hydrazone linkers. Selective release of the drug
at endosomal pH suppressed tumor growth in mice with
enhanced therapeutic efficacy and decreased systemic
toxicity compared to free DOX [19]. These results indicated
that the hydrazone linkages could be stable at physiological
pH 7.4 but degraded effectively at the lower pH of endosomes
and lysosomes (pH 5e6) to release drug. In addition, conju-
gates of doxorubicin and alginate using the cis-aconityl bond,
palitaxel and PEG using the hydrazone bond have been used
for pH-triggered carrier systems [35,36].
The other strategy is attached “titratable” groups in the
copolymers, such as amines or carboxylic acids, to control the
micelle formation by inducing physical dissociation or interior
structural change via variation in pH level. The pH-triggered
release of drugs can be established by protonation of pH-
sensitive polymers that form the hydrophobic core of poly-
meric micelles at physiological pH. Destabilization occurs
when the protonatable groups become charged below the pKa,
leading to repulsion between the polymer chains and
micellar dissociation. Many examples of protonation of poly-
mers that trigger micelle destabilization have been reported,
including poly(histidine) (polyHis), poly(acrylic acid) and pol-
ysulfonamides (Fig. 3). Among of them, polyHis is the most
commonly used pH-sensitive component in micelle-based
pH-triggered release systems since this polymer contains an
imidazole ring endowing it with pH-dependent amphoteric
properties [14,15,17]. In addition, the polyHis presents a strong
endosomolytic property by its proton sponge effect and/or its
interaction with anionic phospholipids comprising the endo-
somal compartments. These properties of polyHis contribute
to the development of a smart micelle system responsive toFig. 3 e Chemical structures of representative pH-sensitive
polymers: (a) poly(histidine); (b) polysulfonamides; (c)
poly(acrylic acid).tumor extracellular pH (pHe) or more acidic endosomal pH.
Lee et al. prepared micelles based on a triblock copolymer
PLA-b-PEG-b-polyHis, which showed triggered release of
doxorubicin when the pH was lowered from 7.4 to 6.0. After
5 h, 40e50% of doxorubicin was released at pH 6.8e6.0, while
60e70%was released after 24 h. Cytotoxicity was 60% at pH 6.8
and 74% at pH 6.0, while onlyminimal release and cytotoxicity
were observed at pH 7.4. These evidences illustrated that
polyHis could triggered drug release in tumor pHe and endo-
somal pH, which resulted in higher cytotoxicity of anticancer
drugs.3. Tumor extracellular pH targeting
The tumor pHe is a consistently distinguished phenotype of
most solid tumors from the surrounding normal tissues. The
mean pH of tumor extracellular fluid is around 7.06 with a
range of 5.7e7.8, lower than physiological pH 7.4, due to the
increased production of glycolysis at tumor sites under either
aerobic or anaerobic conditions. Therefore, this acidic pHe can
be exploited as a drug-release trigger. A tumor pHe-targeting
polymeric micelles with sufficient sensitivity to the weak
acidic pHe encapsulates drug, and the drug should be released
outside tumor cells and then diffuse into the cells, which can
significantly increase the drug accumulation in the tumor
tissue [37e39].
Recent studies have highlighted the development of some
promising carriers with pHe-sensitive and therefore tumor-
selective delivery. In the previous studies, poly(lactide-co-
glycolide) (PLGA)-b-PEG-b-PLGA copolymer is capped by N-
Boc-histidine in each end. Themodification did not impact the
biodegradability and biocompatibility of the polymer. DOX
was incorporated in the micelles. The accumulation DOX
release at 12 h at pH 6.2 was 2-fold than that at pH 7.4. Cellular
uptake of DOX was studied on human breast cancer cell. The
higher uptake under pH 6.2 was attributed to DOX rapid
release at pHe. Therefore, the pH-induced micelle destabili-
zation and triggered release of drug by tumor pHe, after the
accumulation of the micelles in the tumor sites via enhanced
permeability, presented a more effective modality of chemo-
therapy by providing higher local concentration of the drug at
tumor sites and minimal release of the drug from micelles
during blood circulation (pH 7.4) [13]. The above investigations
illustrated that tumor pHe is a more universal way of tumor
targeting.
However, although the drug release from the pH-sensitive
micelles triggered by the tumor pHe can substantially reduce
the systemic toxicity and enhance in vitro and in vivo anti-
cancer activity, it can not solve the problem of MDR of tumor
cells to anticancer drugs.4. Tumor intracellular pH targeting
4.1. Tumor intracellular pH targeting for escaping
lysosome degradation and improving therapeutic efficacy
The endocytic pathway is one of the uptake mechanisms
available to cells. Following micelles internalization, the
Fig. 4 e Schematic representation of pH-responsive
polymeric micelles triggered drug release for extracellular
(a) and intracellular (b) drug targeting delivery [26].
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the endosomal membrane causes an influx of protons which
results in a continuous pH drop as endosomes mature from
early endosomes to late endosomes. The pH decreases even
further when late endosomes fuse with lysosomes.
For the endocytosed polymeric micelles, the fate of these
polymericmicelles relies on the efficiency of lysosomal escape
to a significant extent. Anti-cancer drugs usually loaded in
micelles can be released from micelles in endosomes or ly-
sosomes by pH-controlled hydrolysis after they are taken up
by the cell via the endocytic pathway. If the drugs can not
promptly escape from endosomes, the acidic environment of
lysosomes might activate the lysosomal enzymes for the
degradation of the released drug. This caused a limited de-
livery of therapeutic agents to the intracellular targets. The
inferior drug release inside the tumor cells is one of the key
reasons for low therapeutic efficacy of drug-loaded micelles.
Therefore, the task to facilitate drug escapement from the
endosomal/lysosomal vehicles is very important.
To avoid premature degradation by late endosomes or ly-
sosomes and attain maximum pharmacological effect, a
polymeric micellar delivery system must be developed in
which the drug is released from the endosomes into the
cytosol before degradation in lysosomes. Therefore, the
intracellular pH-sensitive moieties with the ability to desta-
bilize the endosomal membrane or rupture the endosomes
can be used to modify polymeric micelles that facilitate
endosomal escapement. In order to improve the therapeutic
effect of anticancer drugs that target the nucleus or cytosol or
other organelles after cellular uptake, the antitumor drugs
should be released rapidly from the micelles in the acidic
microenvironment of endosomes/lysosomes. In addition, the
use of drug-loaded micelles that destabilizes at an early
endosomal pH of 6.0 should maximize intracellular drug de-
livery andminimize drug release at the extracellular pH and at
the lysosomal pH [40,41].
4.2. Tumor intracellular pH targeting for MDR reversing
Most of the anticancer agents are not very effective in tumor
chemotherapy, due to MDR in various tumor cells. MDR is to
say that cancercellsbecomeresistant to thecytotoxiceffectsof
various structurally and mechanistically unrelated chemo-
therapeutic agents [42]. There are a variety of mechanisms
associated with MDR cells that need to be circumvented for a
successful tumor treatment. P-glycoprotein (P-gp) and other
drug efflux transporters are considered to be critical in pump-
ing anticancer drugs out of cells and causing chemotherapy
failure [43].
Nanotechnology provides an innovative and promising
alternative strategy compared to conventional chemothera-
peutics to circumvent MDR by encapsulating, attaching, and
conjugating drugs to the nanocarriers. One strategy for over-
coming drug resistance is based on the development of new
drug delivery systems to achieve drug accumulation in tumor
tissues, tumor cells, or even subcellular organelles of tumor
cells, such as polymeric micelles [44]. Polymeric micelles have
been shown to bypass the P-gp-based MDR, probably because
cells take up drugs loaded in the carriers via endocytosis
rather than diffusion through the cell membrane where P-gpis located. However, the plain micelles have the relative slow
drug release, and the lower intracellular drug concentration
could fail to reach the optimum therapeutic threshold
promptly, which may contribute to the development of MDR
in tumor cells.
The rapid drug release could provide the sufficient drug
concentration and kill the tumor cells before they acquire the
ability to against the drug. Therefore, the quick drug release is
critical for the chemotherapeutic agents to efficiently kill the
cancer cells without the acquired drug resistance. The
dramatically increased drug concentration in the tumor
microenvironment or cytoplasm may overcome the efflux
receptor (P-gp) or other mechanism-driven drug resistance. In
order to overcome this barrier, to develop micellar systems
with a triggered releasemechanisms is able to release drugs in
response to internal pH stimuli. When polymeric micellar
nanosystems are combined with triggered release mecha-
nisms by endosomal or lysosomal acidity plus endosomolytic
capability, the micellar nanocarriers demonstrate to over-
come MDR of various tumors [16,45] (Fig. 4).5. Multifunctional polymeric micellar
delivery system
5.1. Multifunctional polymeric micelles for drug
targeting
To fully exploit the application of polymeric micellar delivery
systems, development is required regarding drug loading,
long circulation and retention, tumor accumulation, targeting
cellular uptake and intracellular drug release. Although there
are benefits to active targeting, such as enhanced efficacy,
active targeting strategy can result in a high accumulation of
the polymeric micelles, but ineffective drug release lowered
the antitumor efficacy of drugs. Currently, increasing atten-
tion in micelle-based anticancer therapy is given to multi-
functional micelles containing at least two out of three
features regarding targeting ligand and extracellular or
intracellular triggered drug release [46e49]. The combined use
of these approaches will further improve specificity and
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tional polymeric micelles, the combination of multiple
mechanisms for micelle-based drug delivery in anticancer
therapy, characterized by active targeting and pH triggered
release offers challenging opportunities to improve thera-
peutic efficacy. Additionally, the combining active targeting
and pH sensitivity as triggered drug release mechanism re-
sults in more efficient tumor targeting and drug delivery.
Bae et al. designed a pHe-sensitive multifunctional mi-
celles with a ligand that can bind its receptors only if exposed
to an acidic tumor extracellular environment (6.5 < pH < 7.4).
The ligand biotin was anchored to the surface of the micelles
made from the mixed PHis-PEG and PLLA-PEG-PHis-biotin. At
neutral pH, the PHis was insoluble and collapsed on the hy-
drophobic core surface. Thus, the biotin was buried in the PEG
corona and hence not available for binding (Fig. 5). Once the
micelles were exposed to the acidic extracellular of tumors,
the PHis became soluble, and exposed biotin for binding to the
tumor receptors [22].
Torchilin et al. developed a pH-sensitive poly(histidine)-
PEG/DSPE-PEG mixed micelles for achieving the quick intra-
cellular drug release in response to the acidity by an early
endosomal pH of 6.0. In this way, higher intracellular drug
concentrations are obtained. As shown in these studies, when
the ligands conjugated to the micelles bind to their specific
receptors on the cell membrane, the micelles are be inter-
nalized by endocytosis, and the combination of active tar-
geting and triggered release resulted in superior cytotoxicity
and antitumor activity as compared to the non-
multifunctional micelles [14]. Therefore, multifunctional
drug carriers combining the targeting ability and the stimuli
sensitivity prove the concepts of specific tumor cell targeting,
enhanced cellular internalization, and intracellular rapid drug
release.Fig. 5 e (a) Above pH 7.0, biotin anchored on the micelle
core via pH-sensitive PHis is shielded by PEG shell of the
micelle. (b) Biotin is exposed on the surface at acidic
conditions (6.5< pH< 7.0) and can interact with cells,
which facilitates biotin-receptor-mediated endocytosis.
When pH is further lowered (pH< 6.5), the micelle
destabilizes, resulting in enhanced drug release and
disrupted endosomal membrane [30,47].5.2. Multifunctional polymeric micelles for MDR
reversing
Tumor targeting approaches have been developed for
improved antitumor efficacy and reduced toxicity by
increasing cellular accumulation and altering biodistribution
of anticancer drugs through specific cell surface interactions.
Adding a targeting moiety to the surface of polymeric mi-
celles, such as a ligand or an antibody, helps the efficient
cellular uptake and improves drug retention in MDR tumor
cells via receptor-mediated endocytosis, while avoiding P-gp
efflux and being able to enhance the reversal of MDR. Addi-
tional, the endosomal pH triggering anticancer drug release
and the endosomal escaping activity of tumor intracellular
pH-sensitive polymeric micelles allowed cytosolic delivery of
anticancer drug, by avoiding drug sequestration mechanism
in MDR cells and through bypassing MDR proteins expression
on cellular membrane.
When the intracellular pH-triggered drug release is
combined with receptor-mediated active targeting, the
multifunctional polymeric micelles can not only recognize
the cancer cells via receptor-mediated binding, but also
release the drug at tumor sites. This technology may help
trigger the activation of nanosystems to inhibit tumor
growth and reverse MDR. Therefore, designing an advanced
multifunctional micellar delivery system should be a prior-
ity to reverse MDR in cancer chemotherapy. For example,
the protonation of poly(histidine) in the hydrophobic core of
the PEG-poly(histidine)/PEG-poly(L-lactic acid) mixed mi-
celles in the tumor cells resulted in destabilization of micelle
cores and triggered drug release [30]. When these micelles
were targeted to multidrug-resistant MCF-7/Adr cells using
folate labeling, more cells were killed by the drug. The
internalization of micelles proceeds via folate receptor-
mediated endocytosis followed by the triggered drug
release inside the cells, which circumvent drug efflux by P-
glycoprotein pumps located in the cell membrane and
reverse MDR [31].
Bae et al. successfully prepared DOX-loaded pH-sensitive
poly(histidine(His)-co-phenylalanine(Phe))-b-poly(ethylene
glycol) (PEG) and folate conjugated-poly(L-lactic acid) (PLLA)-
b-PEG mixed-micelles in order to challenge MDR in cancers.
This mixed-micelle system composed of poly(His-co-Phe)-b-
PEG (80wt%) and PLLA-b-PEG-folate (20%) released minimal
drug above pH 6.0 and demonstrated the triggered release at
pH 6.0, indicating tuned micelle destabilization at early
endosomal pH. In addition, the research group of Bae suc-
cessfully prepares DOX-loaded poly(histidine)-b-PEG-b-PLLA
pH-sensitive micelles conjugated with folic acid for active
targeting to overcome multidrug resistance. All the above re-
sults showed that when the micelles were internalized into
tumor cells via folate receptor-mediated active endocytosis,
the poly(histidine) block became protonated at endosomal pH,
resulting in micelle destabilization, and subsequent release of
the drug into the cytosol by disruption of the endosomal
membrane, which could effectively kill both DOX-sensitive
and resistant tumor cells through a high dose of DOX in the
cytosol. In this way, drug interaction with the P-gp trans-
porter, present in the cellular membrane and the major cause
of MDR, is minimized [14]. The above results demonstrated
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triggered quick drug release can significantly increase the
intracellular drug concentration and efficiently kill tumor cells
without any risk of developing drug resistance.6. Conclusion
Taking advantages of the altered pH gradients in tumor
extracellular environments and in intracellular compart-
ments, pH-sensitive polymeric micelles have made a signifi-
cant impact on targeted drug delivery, which overcome
limitations of conventional nano drug delivery systems. These
systems increase target drug accumulation at tumor site or at
intracellular cytosolic compartments in tumor cells with less
drug distribution to normal tissues and organs. More impor-
tantly, the intracellular pH-sensitivemicelles offer an efficient
means of overcoming the MDR. The multifunctional poly-
meric micelles with active targeting and pH-sensitive target-
ing strategies demonstrate excellent tumor targeting andMDR
reversal capability. In conclusion, pH-sensitive polymeric
micelles have been emerging as a fascinating class of nano
drug carriers for programmable drug targeting delivery in the
foreseeable future.
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